BioStem Technologies Showcases BioREtain® Technology at SAWC
BioStem Technologies, Inc. (OTC: BSEM), a prominent player in the MedTech sector, focuses on developing and commercializing placental-derived products for advanced wound care. The company recently announced its agenda for the Symposium for Advanced Wound Care (SAWC) Fall meeting in Las Vegas, an essential event for healthcare professionals dealing with chronic wound management.
Collaborative Exhibitions with Venture Medical
During the SAWC Fall meeting, BioStem will co-exhibit alongside its strategic partner, Venture Medical, LLC. This collaboration aims to highlight the combined benefits of BioStem's allograft portfolio and Venture Medical's OneView™ platform. The partnership focuses on improving patient management practices, ensuring healthcare providers have access to optimal skin substitutes for chronic wound treatments.
Key Products Highlighted
Jason Matuszewski, CEO of BioStem, emphasized the importance of their flagship products, AmnioWrap2® and Vendaje AC®, which are exclusively available through Venture Medical. Matuszewski stated, "By employing the Venture OneView™ platform, healthcare providers can enhance patient care and compliance with industry standards, ensuring that needs are appropriately met in the challenging landscape of wound management. Together, we are setting new benchmarks in the market for chronic wound care services."
Engaging Booth Schedule at SAWC
Visitors to the BioStem-Venture booth at SAWC will have the chance to participate in a schedule of interactive sessions led by thought leaders in the field. This includes presentations targeting common misconceptions in wound care, as well as the exploration of effective mobile wound care practices.
Noteworthy Presentations
- "Debunking Wound Care Myths" - Presented by Laura Raty-Kerstetter FNP-C on Friday, 1:00 PM - 2:00 PM.
- "Do's and Don'ts of Mobile Wound Care" - Presented by Louis Heuser, MD on Saturday, 12:30 PM - 1:30 PM.
Additionally, Saturday morning's events will include a morning symposium titled "Navigating the Future of Wound Care," moderated by Michael Desvigne, MD. This symposium will delve into innovative clinical practices, allograft selection strategies, and optimize operational flows in mobile wound care settings.
Scientific Contributions at the Meeting
BioStem is proud to feature three clinical and scientific posters accepted for display at the conference. These research presentations aim to provide insights into the effectiveness of their BioREtain® technology and its comparative advantages against competitor products.
Accepted Poster Presentations
The following research will represent BioStem at SAWC:
Clinical Research:
A Simple Comparison of Real-World Pressure Ulcer Data.
Scientific Research:
A Direct Comparison of Processing Methods for Placental Tissue Allografts.
A Comparison of Sterilization Methods for Dehydrated Birth Tissue.
Dr. Wendy Weston, Vice President of Research and Development at BioStem, remarked, "Our research continues to affirm the impact of our processing techniques on the outcomes of chronic wound treatments, particularly with our patented BioREtain® technology, which aims to maintain the integrity and effectiveness of the allografts provided to patients."
Understanding BioREtain® Technology
At the heart of BioStem's offerings is the innovative BioREtain® method. This proprietary processing technique is designed to preserve the native characteristics of the placental tissue, crucial for effective wound management. The BioREtain® process is a comprehensive six-step approach that ensures the structural and functional integrity of the amniotic tissue. This unique focus on preservation is what differentiates BioStem products in the competitive market of allografts.
Commitment to Quality and Compliance
BioStem Technologies recognizes the importance of quality in advanced wound care. Its operations are aligned with the highest industry standards, having received accreditation from the American Association of Tissue Banks (AATB). This compliance ensures that their allografts meet rigorous guidelines, providing healthcare providers and patients with confidence in their use.
About BioStem Technologies, Inc. (OTC: BSEM)
BioStem Technologies is dedicated to innovating the medical landscape by harnessing the power of perinatal tissue. The company is committed to transforming lives with its quality allografts, products like AmnioWrap® and VENDAJE®, and pioneering processing methods like BioREtain®. Each product is manufactured at their FDA-registered facility in Pompano Beach, Florida, ensuring compliance with both Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP).
Frequently Asked Questions
What products will BioStem showcase at the SAWC meeting?
BioStem will highlight its leading products AmnioWrap2® and Vendaje AC® during the SAWC meeting.
Who is partnering with BioStem at the SAWC Fall meeting?
BioStem is co-exhibiting with Venture Medical, LLC, to showcase their combined innovations in wound care.
What is the focus of BioREtain® technology?
BioREtain® technology aims to preserve the natural properties of placental tissues, enhancing their effectiveness for wound care.
When will the presentations occur at the BioStem booth?
The presentations are scheduled for Friday and Saturday, with specific times listed in the booth schedule.
How does BioStem ensure product quality?
BioStem’s products are manufactured per industry standards and are accredited by the American Association of Tissue Banks (AATB).
